No Data
No Data
chongqing zhifei biological products (300122.SZ): The application for production registration of freeze-dried human rabies vaccine (human diploid cells) has been accepted.
GeLonghui October 16th | Chongqing Zhifei Biological Products (300122.SZ) announced that the company recently received a report from its wholly-owned subsidiary Anhui Zhifei Longkema Biological Pharmaceutical Co., Ltd. (hereinafter referred to as “Zhifei Longkema”), stating that the application for production registration of the freeze-dried human rabies vaccine (human diploid cells) independently developed by Zhifei Longkema has been issued the “Acceptance Notice” (Acceptance No.: CXSS2400112) by the National Medical Products Administration. Rabies is an acute infectious disease caused by the rabies virus, clinically manifested as unique symptoms such as hydrophobia, aerophobia, pharyngeal muscle spasms, and progressive paralysis. Once symptoms appear, the disease
Chongqing Zhifei Biological Products Co., Ltd. (SZSE:300122) Surges 26% Yet Its Low P/E Is No Reason For Excitement
Express News | Zhifei Biological Products Says Board Elects Jiang Rensheng as Chairman
chongqing zhifei biological products' 23-valent pneumonia vaccine joins the "price reduction group" just one year after its launch.
① Chongqing Zhifei Biological Products 23-valent pneumococcal polysaccharide vaccine has lowered its online price by nearly 30% in provinces such as Jiangsu and Jilin; ② Currently, China's pneumococcal vaccine market is showing a competitive situation of "wrestling" between overseas MNCs and domestic companies, and more and more companies are expanding their presence in this field; ③ Industry experts believe that in order to occupy the market, companies can only choose to actively reduce prices.
Chongqing Zhifei Biological Products Co., Ltd. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Zhifei Biotech: 2024 Semi-Annual Report